Literature DB >> 1710306

Palliative therapy of an ectopic Cushing's syndrome due to a metastatic carcinoid tumor.

E Kornely1, R Schlaghecke, F A Horster.   

Abstract

The case of a 39-year-old patient with ectopic Cushing's syndrome due to a metastatic carcinoid tumor is presented. Palliative therapy consisting of 800 mg ketoconazole and 0.3 mg SMS 201-995/die resulted in clinical remission and correction of hypokalemia and hypercortisoluria. Combined therapy was clearly superior to monotherapy with ketoconazole or SMS 201-995, respectively. Side effects were not observed, the tumor masses remained unchanged throughout the observation period of now 19 months.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1710306     DOI： 10.1007/bf01665863

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN： 0023-2173


  6 in total

1.  Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.

Authors:  L K Kvols; C G Moertel; M J O'Connell; A J Schutt; J Rubin; R G Hahn
Journal:  N Engl J Med       Date:  1986-09-11       Impact factor: 91.245

Review 2.  The use of ketoconazole as an inhibitor of steroid production.

Authors:  N Sonino
Journal:  N Engl J Med       Date:  1987-09-24       Impact factor: 91.245

3.  Tumor regression of an ileal carcinoid under the treatment with the somatostatin analogue SMS 201-995.

Authors:  B Wiedenmann; U Räth; R Rädsch; F Becker; B Kommerell
Journal:  Klin Wochenschr       Date:  1988-01-15

4.  Regression of metastatic vipoma with somatostatin analogue SMS 201-995.

Authors:  D Clements; E Elias
Journal:  Lancet       Date:  1985-04-13       Impact factor: 79.321

5.  Somatostatin receptors in human endocrine tumors.

Authors:  J C Reubi; R Maurer; K von Werder; J Torhorst; J G Klijn; S W Lamberts
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

6.  Lung carcinoid with Cushing's syndrome: control of serum ACTH and cortisol levels using SMS 201-995 (sandostatin).

Authors:  P R Hearn; C L Reynolds; K Johansen; N J Woodhouse
Journal:  Clin Endocrinol (Oxf)       Date:  1988-02       Impact factor: 3.478
  6 in total
  2 in total

1.  Is there a therapeutic role for octreotide in patients with ectopic Cushing's syndrome?

Authors:  G I Uwaifo; C A Koch; B Hirshberg; C C Chen; P Hartzband; L K Nieman; K Pacak
Journal:  J Endocrinol Invest       Date:  2003-08       Impact factor: 4.256

Review 2.  Cushing's syndrome due to adrenocorticotropic hormone-secreting metastatic neuroendocrine tumor of unknown primary origin: a case report and literature review.

Authors:  Hayri Bostan; Hakan Duger; Pinar Akhanli; Murat Calapkulu; Tugba Taskin Turkmenoglu; Ayse Kevser Erdol; Serap Akcali Duru; Muhammed Erkam Sencar; Muhammed Kizilgul; Bekir Ucan; Mustafa Ozbek; Erman Cakal
Journal:  Hormones (Athens)       Date:  2021-09-03       Impact factor: 2.885
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.